Application of chondroitin sulfate nano-selenium in preparation of angiogenesis inhibitors and anti-colorectal cancer drugs
The preparation of chondroitin sulfate nanoselenium by combining selenium nanoparticles with chondroitin sulfate nanoselenium has solved the problem of poor toxicity and targeting of selenium compounds in tumor treatment, and achieved effective inhibition of colorectal cancer cells and significant inhibition of angiogenesis. , demonstrates higher biocompatibility and therapeutic effects.
Patent Information
- Application Number
- CN202411017838.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-01-16
- Filing Date
- 2024-07-29
- Publication Date
- 2024-11-15
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing selenium compounds are highly toxic, poorly targeted, and have low bioavailability of chondroitin sulfate, making it difficult to effectively inhibit the growth and angiogenesis of tumor cells.
Combining selenium nanoparticles (SeNPs) with chondroitin sulfate (CS) to prepare chondroitin sulfate nanoselenium (SeCS), chondroitin sulfate nanoselenium (SeCS) through dialysis and freeze-drying, and used to prepare angiogenesis inhibition at specific concentrations and anti-colorectal cancer drugs.
SeCS significantly inhibits angiogenesis and colorectal cancer cell growth, has stronger anti-angiogenesis and anti-colorectal cancer effects, is better than CS and SeNPs alone, and has lower toxicity and higher biocompatibility.
Smart Images

Figure CN118948884A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of anti-tumor drugs, and specifically relates to the application of chondroitin sulfate nano-selenium in the preparation of angiogenesis inhibitors and anti-colorectal cancer drugs. Background Art
[0002] Shark chondroitin sulfate (CS) is a mixed acidic mucopolysaccharide extracted from shark cartilage. It is mainly composed of linear anionic polysaccharides formed by alternating β1-3 and β1-4 glycosidic bonds between D-glucuronic acid (GlcA) and N-acetylgalactosamine (GalNAc). It generally exists in the form of sodium salt. It contains not only chondroitin sulfate A and chondroitin sulfate C, but also chondroitin sulfate D and chondroitin sulfate E that are not found in poultry. Shark chondroitin sulfate not only has the efficacy of treating osteoarthritis, rheumatoid arthritis, preventing arteriosclerosis and neurovascular glaucoma, but also has anti-cancer activity, promotes the growth of synapses and prevents memory loss in the elderly. It has been widely used in food, health products, cosmetics and medicine industries.
[0003] Selenium is an important trace element necessary for the human body. Selenium as a drug for tumor treatment has been increasingly studied, but selenium compounds, as an organic selenium preparation, have high toxicity and poor targeting. As a new type of single substance and elemental selenium, nanoselenium (Selenium Nanoparticles, SeNPs) has higher bioavailability, stronger biological activity and lower toxicity compared with other forms of selenium such as inorganic selenium. As a "therapeutic drug carrier", it has the advantages of good biocompatibility, high loading rate, low toxicity, easy synthesis and easy storage.
[0004] Tumor is one of the most serious diseases in the world today. It is caused by the body being affected by a variety of carcinogenic factors, which causes a certain local cell to grow abnormally at the genetic level, thus forming a tumor due to abnormal proliferation. Tumor treatment is usually chemotherapy, which has serious side effects, so it is very important to develop a natural drug with less toxic side effects.
[0005] Colon cancer is the most common digestive tract malignancy and a serious threat to human health. Due to its own physical and chemical properties, the nano drug delivery system can effectively improve the pharmacokinetic properties and protect the encapsulated drugs; it has tumor-targeted delivery capabilities and improves drug bioavailability; it can also reduce drug distribution in non-targeted tissues and reduce drug toxicity and side effects. Summary of the invention
[0006] The present invention combines SeNPs and CS to prepare chondroitin sulfate nano-selenium (SeCS), which solves the problems of instability of SeNPs and low bioavailability of CS, and also achieves the synergistic anti-tumor effect of SeNPs and CS, especially the anti-colorectal cancer effect, and provides the application of chondroitin sulfate nano-selenium in the preparation of angiogenesis inhibitors and anti-colorectal cancer drugs.
[0007] In view of this, the first object of the present invention is to provide the use of chondroitin sulfate nano-selenium in the preparation of angiogenesis inhibitors.
[0008] Preferably, the angiogenesis inhibitor is a drug having at least one of the following uses (1)-(4):
[0009] (1) Inhibit the formation of endothelial cell lumen;
[0010] (2) Inhibit angiogenesis;
[0011] (3) Inhibit the growth and migration of vascular endothelial cells;
[0012] (4) Inhibit endothelial cell invasion.
[0013] Preferably, the concentration of chondroitin sulfate nano-selenium in the angiogenesis inhibitor is 0.02-0.2 mg / mL.
[0014] The second object of the present invention is to provide a method for non-therapeutic inhibition of angiogenesis in vitro, wherein vascular endothelial cells are cultured in the presence of chondroitin sulfate nano-selenium, thereby inhibiting their angiogenesis.
[0015] The third object of the present invention is to provide the use of chondroitin sulfate nano-selenium in the preparation of anti-colorectal cancer drugs.
[0016] Preferably, the anti-colorectal cancer drug is a drug having at least one of the following uses (1)-(2):
[0017] (1) Inhibit the growth of colorectal cancer cells;
[0018] (2) Inhibit the growth of human colon cancer.
[0019] Preferably, the chondroitin sulfate nano-selenium is prepared by the following method:
[0020] Sodium selenite and ascorbic acid were dissolved in a 0.1 mg / mL aqueous solution of chondroitin sulfate, wherein sodium selenite was added in an amount with a final concentration of 0.173 mg / mL in the solution, and ascorbic acid was added in an amount with a final concentration of 1.408 mg / mL in the solution; the mixture was stirred at 25°C for 3 hours, and then the reaction solution was dialyzed in double distilled water with a dialysis bag for 48 hours, and the retained liquid in the dialysis bag was freeze-dried to obtain chondroitin sulfate nano-selenium.
[0021] Preferably, the dialysis bag model is MW:3500, and the molecular weight cut-off is 3500Da. The chondroitin sulfate is shark chondroitin sulfate. The structural unit of shark chondroitin sulfate is a linear anionic polysaccharide composed of D-glucuronic acid (GlcA) and N-acetylgalactosamine (GalNAc) alternately linked by β1-3 and β1-4 glycosidic bonds.
[0022] Preferably, the dosage of the chondroitin sulfate nano-selenium is 5-10 mg / kg.
[0023] The fourth object of the present invention is to provide an in vitro non-therapeutic method for inhibiting the growth of colorectal cancer cells, by culturing colorectal cancer cells in the presence of chondroitin sulfate nano-selenium, thereby inhibiting their growth.
[0024] The experimental results of the present invention show that chondroitin sulfate nano-selenium has a strong inhibitory effect on angiogenesis, and is significantly stronger than the inhibitory effect of CS and SeNPs, and has synergistic synergy; at the same time, chondroitin sulfate nano-selenium inhibits the growth of human colorectal adenocarcinoma cells and HT29 human colon cancer nude mouse transplanted tumors, which has synergistic synergy relative to CS and SeNPs, and the inhibitory effect is better than the positive control bevacizumab. Therefore, chondroitin sulfate nano-selenium has a strong anti-angiogenesis and anti-colorectal cancer effect, and can be used to prepare anti-angiogenesis and anti-colorectal cancer drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] Figure 1 The effects of different concentrations of bevacizumab (Bev), SeCS, CS and SeNPs on the ability of cell tube formation in human umbilical vein endothelial cells; A is the microscopic photos of the tubes formed in each group at different concentrations (200×); B is the number of tube branches formed in each group at a concentration of 200μg / mL; C is the total length of the tubes formed in each group at a concentration of 200μg / mL; D is the number of tubes formed in each group at a concentration of 200μg / mL; compared with the blank control group (Con): *P<0.05; compared with the Bev group: #P<0.05.
[0026] Figure 2 The effects of SeCS on chicken embryo chorioallantoic membrane, where A is a morphological diagram showing the effects of 200 μg / mL CS, SeNPs, SeCS, and Bev on angiogenesis in chicken and swine chorioallantoic membrane; B is the effects of 200 μg / mL CS, SeNPs, SeCS, and Bev on the angiogenesis rate in chicken and swine; compared with the control group: *P<0.05.
[0027] Figure 3 The effects of 200 μg / mL CS, SeNPs, SeCS, and Bev on the survival rate of HUVEC cells.
[0028] Figure 4 The effects of 200 μg / mL CS, SeNPs, SeCS, and Bev on the survival rate of human colorectal adenocarcinoma cells (Caco-2);
[0029] Compared with the control group: **P<0.01; Compared with the Bev group: ##P<0.01.
[0030] Figure 5 The effects of different treatments on the scratch healing ability of HUVEC cells; A is the microscopic photos (200×) of scratched HUVEC cells treated with 200 μg / mL CS, SeNPs, SeCS, and Bev for 0 and 24 h; B is the bar graph of the scratch healing rate of HUVEC cells; compared with the control group: ****P<0.0001.
[0031] Figure 6 The effects of different treatments on the invasion ability of HUVEC cells; A is the microscopic photograph (200×) of HUVEC cell invasion after 24h of treatment with 200μg / mL CS, SeNPs, SeCS, and Bev; B is the bar graph of HUVEC cell invasion rate; compared with the control group: ****P<0.0001; compared with the Bev group: ####P<0.0001.
[0032] Figure 7 The effect of SeCS on nude mouse tumors in vivo; A is the weight of nude mice with tumors; B is the volume of nude mice with tumors; C is the morphology of nude mice with tumors; D is the weight of nude mice with tumors; EG is the activities of AKP, AST, and CAT; N=6, compared with the control group: *P<0.05, ****P<0.0001.
[0033] Figure 8 A is a mouse in vivo imaging image; A is a mouse in vivo fluorescence imaging image; B is a mouse visceral fluorescence imaging image; N=3. DETAILED DESCRIPTION
[0034] The following examples are provided to further illustrate the present invention, rather than to limit the present invention.
[0035] Example 1
[0036] 1 Materials and methods
[0037] 1.1 Materials and reagents
[0038] Chondroitin sulfate (95% purity, product number C107703 Chondroitin sulfate (shark)) was purchased from Aladdin Reagent (Shanghai) Co., Ltd.; Caco-2 human colorectal adenocarcinoma cells were provided by the Chinese Academy of Sciences (Shanghai) Cell Bank, HUVEC human umbilical vein endothelial cells were provided by the American ATCC Cell Bank, HT29 human colon cancer cells (product number CL-0118) were purchased from Wuhan Pronocell Life Science Co., Ltd., China; Matrigel matrix gel containing phenol red and oxalic acid crystal violet staining solution (0.1%) was purchased from the American ATCC; 4% paraformaldehyde was purchased from Beijing Solebao Company Fetal bovine serum (Cat. No. 10270-106), PBS (Cat. No. C10010500BT), DMEM high glucose medium (Cat. No. C11995500BT), 0.25% trypsin solution (Cat. No. 25200072) and penicillin-streptomycin double antibody solution (Cat. No. 15140122) were all purchased from Gibco, a subsidiary of Thermo Fisher Scientific (China) Co., Ltd.; CCK8 was purchased from Biosharp Biotechnology Co., Ltd.; DMSO (dimethyl sulfoxide, Cat. No. R012316) was purchased from Shanghai Yien Chemical Technology Co., Ltd. Sodium selenite (Na 2 SeO 3 ≥98% purity, product number S5261-25G) was purchased from Sigma; ascorbic acid (vitamin C, product number S13001) was purchased from Shanghai Yuanye Biotechnology Co., Ltd.; bevacizumab injection (Bevacizumab, hereinafter referred to as bevacizumab, trade name Avastin) was purchased from Qilu Pharmaceutical Co., Ltd.; cy5.5 (product number Y09955001) was purchased from Xinwei Chuang Biotechnology (Chongqing) Co., Ltd.; AST (product number C010-2-1), AKP (product number A059-2), CAT (product number A007-1-1) assay kits were purchased from Nanjing Jiancheng Bioengineering Institute.
[0039] 1.2 Instruments and Equipment
[0040] AUW120 electronic balance, Shimadzu Corporation, Japan; XRDKQ-500DB CNC ultrasonic cleaning machine, Kunshan Ultrasonic Instrument Co., Ltd.; VarioskanFlash multifunctional microplate reader, ThermoFisher Scientific, USA; double-beam UV-visible spectrophotometer, Beijing Spectrum Analysis General Instrument Co., Ltd.; DHG-9070A blast drying oven, Shanghai Yiheng Science Co., Ltd.; HL-6 digital display constant temperature water bath, Changzhou Aowa Instrument Co., Ltd.; Eppendorf5810R refrigerated centrifuge, Eppendorf, Germany; FD8508 vacuum freeze dryer, Ilshin, South Korea; EYELA rotary evaporator, EYELA, Japan; Bruker Tensor-27 Fourier transform infrared spectrometer, Bruker, Germany; Agilent 1100 high performance liquid chromatograph, Agilent, USA; Leica DMI4000B intelligent inverted fluorescence microscope, Ernst Leitz, Germany; Tianneng Tanon 5200 fully automatic chemiluminescence imaging analysis system, Shanghai Tianneng Technology Co., Ltd.; small living animal fluorescence imager, Jena Analytical Instruments (Beijing) Co., Ltd.
[0041] 1.3 Experimental methods
[0042] 1.3.1 Preparation of SeCS
[0043] The preparation method of SeCS is as follows: sodium selenite (Na 2 SeO 3 ) 5.19 mg and ascorbic acid (vitamin C) 42.24 mg were dissolved in 30 mL of 0.1 mg / mL chondroitin sulfate (CS) aqueous solution and stirred at 25°C for 3 h. The reaction solution was then dialyzed in double distilled water using a dialysis bag (MW: 3500) for 48 h, and the retained liquid in the dialysis bag was freeze-dried to obtain chondroitin sulfate nano-selenium (SeCS), which was dark red in color.
[0044] The preparation method of SeNPs used in the following experiments is the same as the preparation method of SeCS described above, except that 30 mL of 0.1 mg / mL chondroitin sulfate (CS) aqueous solution is replaced with 30 mL of water to prepare nano-selenium (SeNPs).
[0045] In the following experiments, the bevacizumab group diluted the bevacizumab injection product (the effective concentration of bevacizumab in this product is 25 mg / mL) to the target concentration set in the experiment with the experimental solution; the SeCS group, CS group, and SeNPs group respectively quantitatively weighed the prepared chondroitin sulfate nano-selenium (SeCS), chondroitin sulfate (CS), and prepared nano-selenium (SeNPs) according to the target concentration set in the experiment, dissolved them with the experimental solution, and diluted them to the target concentration.
[0046] 1.3.2 Cell culture
[0047] After recovery, HUVEC and Caco-2 cells were placed in DMEM high-glucose medium containing 10% fetal bovine serum and 1% double antibody solution, and the cell culture flasks were placed at 37°C and 5% CO 2 The cells were cultured statically in an incubator at 4 °C. When the cell confluence reached 70% to 80%, they were passaged. The cells with good growth and in the logarithmic growth phase were used for the following experiments.
[0048] 1.3.3 Tube formation experiment
[0049] Take Matrigel out of the -20℃ freezer and place it in a 4℃ refrigerator to thaw overnight to make it liquid. Precool the pipette tip and 24-well plate before the experiment, and all operations should be performed on ice.
[0050] Inject Matrigel gel with a volume ratio of 2:1 (diluted with PBS) into a 24-well plate, 300 μL per well, and gently shake it to evenly cover the bottom of the plate to avoid the generation of bubbles. Then place the plate at 37°C and 5% CO 2 Incubator for 30 min to allow the gel to solidify.
[0051] The digested and washed HUVEC cells were collected in a culture medium containing 2% fetal bovine serum, and 2×10 5 Cells / 500 μL were inoculated in a 24-well plate covered with Matrigel. The test groups were 50 μg / mL, 100 μg / mL, 200 μg / mL, and 400 μg / mL of bevacizumab, SeCS, CS, and SeNPs (prepared with complete culture medium as solution). All test groups contained 20 ng / mL of VEGF, and the control group contained 20 ng / mL of VEGF. Three replicate wells were set for each dose group.
[0052] After culturing for 4-6 h, the 24-well plate was removed, and 6 fields of view were randomly selected under a microscope to take pictures. The number of duct intersections, the number of lumen branches, and the length of lumen formation were calculated using Image-Proplus6.0 image processing software.
[0053] 1.3.4 Effect of SeCS on angiogenesis in chick chorioallantoic membrane (CAM)
[0054] 1.3.4.1 Chicken embryo incubation
[0055] Select fresh (within 1 week) fertilized eggs with similar mass (50±5)g, uncontaminated and undamaged skin, wash them, wipe the surface with 75% alcohol for disinfection, and incubate them in a constant temperature incubator at (37.5±0.5)℃ and relative humidity of 40% to 70%. The blunt end (large end) of the chicken embryo faces upward and is tilted at 45°. Turn the eggs 2 to 4 times a day to promote the movement of the amniotic membrane, prevent the embryo from adhesion, and ensure the supply of oxygen.
[0056] On the fifth day of culture, take the eggs to a dark room and observe their growth under an egg-checking lamp. Select live embryo eggs with shadows of chicken embryos and clear blood vessels, draw the air chamber range with a pencil, and place them in an incubator for further culture.
[0057] 1.3.4.2 Vector preparation
[0058] Select 0.22μm mixed cellulose microporous filter membrane as the carrier, use a puncher to make a circular filter paper with a diameter of 0.5cm, soak it with double distilled water, sterilize it with wet heat, and dry it for use. Sterilize it with high pressure wet heat at 121℃ for 20min, soak it in sterile distilled water twice, and use it as a drug carrier for use.
[0059] 1.3.4.3 Grouped medication
[0060] Take out the 7-day-old chick embryos and check the embryonic incubation and survival under the egg-light. The main blood vessels of the allantoic membrane of the well-incubated chick embryos are clear. Discard dead sperm eggs and eggs with poor embryo development, and select well-developed chick embryos and divide them into 5 groups, 10 in each group.
[0061] On the 8th day, the embryo was disinfected twice with alcohol cotton balls. An opening was made on the shell under sterile conditions on a clean bench to expose the chorioallantoic membrane. A medical grinding wheel was then used to grind a circle with a diameter of about 1.5 cm in the air chamber area at the top of the embryo. The eggshell and outer shell membrane in the circle were carefully removed with tweezers. A small hole was gently pierced in the inner shell membrane with a syringe needle, and then the inner shell membrane was gently peeled off with ophthalmic tweezers to expose the CAM membrane below (if it is difficult to peel off, a drop of physiological saline was added). A circular filter paper with a diameter of 0.5 cm was used as a carrier and placed in the vascular-free or less vascular area of the CAM of each group. Then 20 μL of the negative group (only containing physiological saline) and the experimental group (200 μg / mL bevacizumab, SeCS, CS or SeNPs) were respectively taken with a pipette and dropped on the carrier. Then it was sealed with a sterile sealing film to create a pseudo-air chamber, and continued to incubate after labeling. During incubation, the window was facing up, and the eggs were no longer turned. The box was opened for ventilation twice a day.
[0062] 1.3.4.4 Preparation of chorioallantoic membrane photographs / CAM model
[0063] After 48 hours, the chick embryos were removed, the transparent tape was removed, and the eggshell around the pseudo-air chamber was peeled off to fully expose the chorioallantoic membrane. 0.5 mL of a mixture of methanol and acetone (1:1) was dripped onto the membrane and fixed at room temperature for 15 minutes. The chorioallantoic membrane with a diameter of 1.5 cm centered on the pellicle was cut off, and the eggshell and eggshell membrane above the CAM plane were removed with tweezers to expose the CAM to the greatest extent, and the CAM was photographed in situ with a digital camera.
[0064] 1.3.4.5 Vessel Count
[0065] In the photo, the center of the drug film circle is taken as the center. The blood vessels with a diameter of 1 cm and an angle of less than 45° with the radius of the drug film can be included in the counting. The blood vessels on the CAM are counted using a computer image processing system (Image J). Blood vessels with a diameter less than 0.1 mm are medium and small blood vessels, and those greater than 0.1 mm are large blood vessels. Only medium and small blood vessels are included in the counting range, and then statistical processing is performed using SPSS10.0 software, expressed as x±s, and variance analysis is used to compare the two groups between different drugs and the positive control group and the blank group. The photos with clear pictures are selected and the blood vessels are counted on the computer at the same magnification. The image is read in using the image processing software ImageJ, and the blood vessel area of each group is counted, and the percentage of the blood vessel area to the total area of the CAM is calculated. The calculation formula is as follows: Angiogenesis rate (%) = (angiogenesis area at the eggshell window site / allantoic membrane area at the eggshell window site) × 100%, and SPSS17.0 is used for statistical processing. One-way variance analysis is performed, and all data are expressed as mean ± standard deviation (x±s). P<0.05 indicates a significant difference, and P<0.01 indicates an extremely significant difference.
[0066] 1.3.5 CCK8 assay to determine the inhibitory effect of SeCS on the growth of human umbilical vein endothelial cells
[0067] HUVEC cells were seeded in 96-well culture plates, with 5×10 3 cells / 100 μL / well, blank wells were not inoculated with cells, and the cells were placed at 37°C and 5% CO 2 Culture in a cell culture incubator with saturated humidity. After the cells were cultured for 24 hours to confirm that they were attached to the wall, the culture medium was removed and the same concentration of SeCS (200 μg / mL) was added. Serum-free culture medium was added to the negative wells and blank wells as controls, 100 μL per well. After the cells were cultured for 24 hours, the culture medium was aspirated, and dead cells were washed with PBS. 10 μL CCK8 was added to each well and incubated for 3 hours. The 450nm value was measured by an enzyme marker, and the cell growth inhibition rate was calculated according to the following formula and plotted. Six parallel wells were set for each dose concentration, and the test was repeated 3 times. Inhibition rate (%) = (OD value of negative well - OD value of test well) / (OD value of negative well - OD value of blank well) × 100%.
[0068] 1.3.6 CCK8 assay to determine the inhibitory effect of SeCS on the growth of human colorectal adenocarcinoma cells
[0069] Caco-2 cells were inoculated into 96-well culture plates, with 8×10 3 cells / 100 μL / well, blank wells were not inoculated with cells, and the cells were placed at 37°C and 5% CO 2 Culture in a cell culture incubator with saturated humidity. After the cells are cultured for 24 hours to confirm that they are attached to the wall, the culture medium is removed and the same concentration of SeCS (200 μg / mL) is added. Serum-free culture medium is added to the negative wells and blank wells as a control, 100 μL per well. After the cells are cultured for 24 hours, the culture medium is aspirated, and dead cells are washed away with PBS. 10 μL CCK8 is added to each well and incubated for 1.5 hours. The 450nm value is measured by an enzyme reader. The cell growth inhibition rate is calculated according to the following formula and plotted. Six parallel wells are set for each dose concentration, and the test is repeated 3 times. Inhibition rate (%) = (OD value of negative well - OD value of test well) / (OD value of negative well - OD value of blank well) × 100%.
[0070] 1.3.7 Effect of SeCS on migration of human umbilical vein endothelial cells
[0071] The scratch injury model was used to analyze and compare the migration ability of HUVEC cells at different concentrations in two dimensions. The specific operation steps are as follows: Use a ruler and a marker to draw 3-5 positioning lines at 0.5-1 cm intervals on the back of a 24-well plate, digest the cells with trypsin, and press 2.5×10 5 Cells / 500 μL were seeded into 24-well culture plates and incubated at 37°C and 5% CO 2 Cultured under the conditions for 24 h.
[0072] The next day, place a ruler under ultraviolet irradiation on a clean bench for more than 30 minutes, and refrigerate a 200μL pipette tip in a 4°C refrigerator overnight: take the 24-well plate with cells completely attached to the wall out of the cell culture incubator, operate on the clean bench, aspirate the supernatant culture medium and rinse twice with sterile PBS, use a sterile ruler as a reference and perpendicular to the positioning line, use a 200μL pipette tip to gently scratch the cell surface, thereby forming a cell-free straight line in each well of the 24-well cell culture plate. Draw 3 cell-free straight lines in each well, wash gently 2-3 times with PBS preheated at 37°C to remove floating cell debris, add 500 μL / well of culture medium preheated at 37°C containing 200 μg / mL bevacizumab, SeCS, CS, and SeNPs (the drugs are first dissolved in serum-free culture medium (basic culture) and filtered through a 0.22 μm filter membrane), set up 3 replicate wells for each dose, and set up a positive control group at the same time, and continue to culture in an incubator; after culturing for 0.5-1h (waiting for cells to recover), take this time as the zero time point, observe cell migration under an inverted microscope (200×) at 0 and 24h, measure the width of 5 scratches in each well (i.e., the two ends, the midpoint, the left 1 / 4 and the right 1 / 4) and calculate the average value until the cells are completely confluent. Three parallel wells are set for each group of cells. The cell scratch healing rate was calculated according to the following formula: Cell scratch healing rate = (initial scratch width - scratch width after 24 hours) / initial scratch width × 100%.
[0073] 1.3.8 Effect of SeCS on the invasion of human umbilical vein endothelial cells
[0074] Take out the Matrigel from -20℃ and put it in a 4℃ refrigerator to dissolve overnight. Precool the 200μL pipette tip overnight before the experiment. During the experiment, cover the upper and lower layers of the filter membrane with Matrigel (diluted with PBS) at a volume ratio of 1:30 and 1:100 respectively, taking care not to generate bubbles, and place it at 37℃, 5% CO 2 Incubate in a 5% CO incubator for 30 minutes to allow the gel to solidify. After the Matrige gel solidifies, discard the supernatant for later use.
[0075] After culturing the cells in serum-free medium (basal medium) for 12 h, single-cell suspension was prepared using 0.125% trypsin digestion and serum-free medium, and the concentration was adjusted to 5×10 5 600 μL of complete medium was added to the 24-well culture plate, and then the Transwell invasion chamber was immersed. Then, 200 μL of cell suspension (i.e., 5×10 4 cells / well, resuspended in medium): 37°C, 5% CO 2After 24 h of culture, the Transwell chamber was taken out and then placed in an incubator (37°C, 5% CO 2 ) for 48 hours, remove the upper chamber and rinse repeatedly with PBS, add 10% ethanol to fix for 30 minutes, stain with crystal violet for 5 minutes, wipe the unmigrated cells in the upper chamber with a cotton swab dipped in PBS, (200×) select 6 fields of view (one each in the upper, lower, left, right, and two in the center) to count cells (purple) and observe and count the number of cells that pass through the chamber. The invasion rate is calculated as shown in the formula: Invasion rate (%) = number of invasive cells in each group / number of invasive cells in the control group × 100%.
[0076] 1.3.9 Study on the inhibitory effect of SeCS on the growth of HT29 human colon cancer transplanted tumors in nude mice
[0077] 40 female BALB / c nude mice of SPF grade, 4-6 weeks old, weighing (15-20) g, were purchased from Zhuhai Beston Biotechnology Co., Ltd. The environment was strictly controlled with 12h light and 12h dark, with relative humidity set at 60%±5%, temperature at 22℃±2℃, and free access to food and water during the period. The drinking water was sterilized distilled water from the experimental animal center. The animal was raised and handled in accordance with the Guidelines for the Care and Use of Laboratory Animals and approved by the Animal Care and Use Committee (2022 Animal Review
[00941] ). The nude mice were allowed to adapt to the environment for one week before the experiment was carried out. The mice were injected with 2×10 6 HT29 cells. The mice were divided into 4 groups (n=10) until the transplanted tumor model was successfully established. The groups were normal saline group (Con), Bev group (5 mg / kg), SeCS-L group (5 mg / kg), and SeCS-H group (10 mg / kg), and the drugs were injected into the tail vein. Among them, Bev was dissolved in normal saline and injected once every 3 days; SeCS was dissolved in normal saline and injected once every 2 days. The tumor (long diameter and short diameter) was measured with a vernier caliper every two days, and the tumor volume was calculated to monitor the tumor growth. The formula (tumor volume (mm 3 ) = tumor long diameter (mm) × tumor short diameter (mm) 2 / 2) Monitor tumor volume. After 14 days of treatment, all mice were killed. The mouse tumors were removed, weighed and photographed. To determine whether SeCS affects the liver function of mice, blood samples were collected for biochemical analysis, mouse serum was obtained by centrifugation, and these functional parameters were tested using AST, AKP, and CAT detection kits.
[0078] 1.3.10 In vivo fluorescence imaging of nude mice
[0079] In order to further detect the pathway of SeCS in nude mice and whether it aggregates and acts on tumors, cy5.5-labeled samples cy5.5 and SeCS-cy5.5 were prepared and stored in the dark. Nude mice bearing colorectal cancer HT29 were randomly divided into two groups. When the tumor volume reached 70 mm 3 At the same time, cy5.5 and SeCS-cy5.5 (100 μL / mouse, cy5.5 fluorescence dose of 0.02 mg / kg) were respectively administered by tail vein injection. The nude mice were anesthetized by intraperitoneal injection of tribromoethanol. When the nude mice were stably in anesthesia, they were placed in a small animal live imaging instrument for photography, and live imaging images at different time points were recorded.
[0080] 2 Results Analysis
[0081] 2.1 Tube formation experiment
[0082] At 200 μg / mL, the number of lumen branches and the total length of the lumen in the SeCS group were significantly lower than those in the blank control group and SeNPs group ( Figure 1 , P<0.05). The inhibition rate of 200μg / mL chondroitin sulfate nano-selenium (SeCS) on the lumen formation of human umbilical vein endothelial cells (calculated by the number of lumen branches) can reach 54.79%, which is significantly higher than the inhibition rate of lumen formation of CS group (25.5%) and SeNPs group (13.84%). The results showed that 200μg / mL SeCS had the best anti-lumen formation effect. Therefore, 200μg / mL SeCS concentration was used throughout the in vitro experiment.
[0083] 2.2 Effect of SeCS on CAM angiogenesis
[0084] After 48 hours of drug administration, the angiogenesis rate in the SeCS group was 59.77±9.658%, which was lower than that in the positive control group (bevacizumab group) (67.39±13.13%), and significantly lower than that in the CS group (86.82±7.43%) and the SeNPs group (94.52±8.31%). Figure 2 The results showed that after CS combined with SeNPs to form SeCS, the ability to inhibit angiogenesis increased significantly (P<0.05), with obvious synergistic effect.
[0085] 2.3 CCK8 assay to determine the inhibitory effect of SeCS on the growth of human umbilical vein endothelial cells
[0086] After 24 h of sample treatment, the survival rate of HUVEC cells in the SeCS group was 80.67±4.06%, which was lower than that of the bevacizumab group (85.48±4.38%). Figure 3), while there was no significant difference between the SeNPs group, CS and the blank control group. After CS combined with SeNPs to form SeCS, the ability to inhibit HUVEC cell survival was enhanced and was better than the positive control group.
[0087] 2.4 CCK8 assay to determine the inhibitory effect of SeCS on the growth of human colorectal adenocarcinoma cells
[0088] After 24 h of sample treatment, the survival rate of Caco-2 cells in the SeCS group was 69.63±12.00%, which was lower than that of the bevacizumab group (88.39±4.58). Figure 4 ); the survival rates of the CS group were 96.15±1.52% and the SeNPs group were 99.98%, which were not significantly different from the blank control group. After CS combined with SeNPs to form SeCS, the ability to effectively inhibit the survival of colorectal cancer cells was significantly enhanced (P<0.01), and was significantly better than the positive control group (P<0.01).
[0089] Effects of 2.5SeCS on the Migration of Human Umbilical Vein Endothelial Cells
[0090] After 24 hours, the scratch healing rate of HUVEC cells in the SeCS group was 33.11±0.81% ( Figure 5 ), which was significantly lower than that of the blank control group (P<0.0001), and lower than the cell healing rate of the positive control group (47.39±0.815), and significantly lower than the cell healing rates of the SeNPs group (59.95±0.72%) and the CS group (55.53±2.02%). After CS combined with SeNPs to form SeCS, the ability to inhibit cell healing increased significantly.
[0091] Effect of 2.6SeCS on the invasion of human umbilical vein endothelial cells
[0092] After SeCS treatment, the invasion rate of HUVEC cells was 34.42±2.13% ( Figure 6 ) and was significantly lower than the invasion rate of the positive control group (62.43±2.86%) (P<0.0001), and was significantly lower than the invasion rates of the CS-treated group (68.17±0.60%) and the SeNPs-treated group (97.74±1.30%), indicating that SeCS had a stronger ability to inhibit cell invasion than CS and SeNPs, and had obvious synergistic effect.
[0093] 2.7 Evaluation of the anti-tumor efficacy of SeCS in vivo
[0094] To further study the antitumor effect of SeCS in vivo, a HT29 colon cancer xenograft model in nude mice was established. Figure 7As shown in A, after SeCS treatment, the body weight and mortality of mice did not decrease significantly, indicating that SeCS has good biocompatibility. Compared with the control group, SeCS significantly inhibited tumor growth during administration ( Figure 7 B and C, P < 0.0001). Tumor weight was also inhibited by SeCS treatment ( Figure 7 D, P < 0.05), and was concentration-dependent. In addition, blood from the control group and SeCS-treated group was collected for toxicity tests. Liver function indices (AST, AKP, CAT) were examined. Figure 7 EG showed that SeCS had almost no significant effect on the liver function of nude mice.
[0095] 2.8 In vivo fluorescence imaging of nude mice
[0096] The distribution and metabolism of SeCS-cy5.5 in nude mice ( Figure 8 A), mice that were not injected with cy5.5 did not contain fluorescent substances. At 0.5h, SeCS-cy5.5 was distributed throughout the body of the nude mice, and fluorescence appeared at the tumor site. The fluorescence intensity was not significantly different from that at other sites, indicating that SeCS had entered the tumor and was being distributed and metabolized. At 1h, the fluorescence intensity at the tumor site of the nude mice weakened, indicating that some SeCS-cy5.5 had been metabolized: at 2h and 4h, a strong fluorescence signal appeared at the urethra of the nude mice, indicating that SeCS-cy5.5 had been circulated in the body, entered the bladder from the kidneys, and was excreted from the body in the form of urine. After 6h, there was almost no fluorescence at the tumor site of the cy5.5 group, indicating that the metabolism rate of cy5.5 in tumor-bearing nude mice was faster than that of SeCS-cy5.5. Compared with cy5.5, cy5.5 combined with SeCS can prolong the drug's action time in the body. From the anatomical diagram ( Figure 8 B) It can be seen that SeCS mainly stays in the lungs and tumor sites. The accumulation of SeCS in tumors indicates that it has good targeting ability in anti-tumor therapy.
Claims
1. Application of chondroitin sulfate nano-selenium in the preparation of angiogenesis inhibitors.
2. The use according to claim 1, characterized in that: The angiogenesis inhibitor is a drug having at least one of the following uses (1)-(4): (1) Inhibit the formation of endothelial cell lumen; (2) Inhibit angiogenesis; (3) Inhibit the growth and migration of vascular endothelial cells; (4) Inhibit endothelial cell invasion.
3. The use according to claim 1, characterized in that: The concentration of chondroitin sulfate nano-selenium in the angiogenesis inhibitor is 0.02-0.2 mg / mL.
4. A method for non-therapeutic inhibition of angiogenesis in vitro, characterized in that: Vascular endothelial cells were cultured in the presence of chondroitin sulfate nano-selenium, thereby inhibiting their angiogenesis.
5. Application of chondroitin sulfate nano-selenium in the preparation of anti-colorectal cancer drugs.
6. The use according to claim 5, characterized in that: The anti-colorectal cancer drug is a drug having at least one of the following uses (1)-(2): (1) Inhibit the growth of colorectal cancer cells; (2) Inhibit the growth of human colon cancer.
7. The use according to claim 5, characterized in that: The chondroitin sulfate nano-selenium is prepared by the following method: sodium selenite and ascorbic acid are dissolved in a 0.1 mg / mL chondroitin sulfate aqueous solution, wherein sodium selenite is added in an amount of 0.173 mg / mL in the solution, and ascorbic acid is added in an amount of 1.408 mg / mL in the solution; stirring at 25° C. for 3 hours, then dialyzing the reaction solution in double distilled water with a dialysis bag for 48 hours, and taking the retained liquid in the dialysis bag and freeze-drying it to obtain the chondroitin sulfate nano-selenium.
8. The use according to claim 7, characterized in that: The dialysis bag model is MW: 3500, and the molecular weight cut-off is 3500Da; the chondroitin sulfate is shark chondroitin sulfate.
9. The use according to claim 5, characterized in that: The dosage of the chondroitin sulfate nano-selenium is 5-10 mg / kg.
10. A method for non-therapeutic in vitro inhibition of colorectal cancer cell growth, characterized in that: Colorectal cancer cells were cultured in the presence of chondroitin sulfate nanoselenium, thereby inhibiting their growth.
Citation Information
Patent Citations
Straw mushroom polysaccharide-selenium nanoparticle compound with tumor cell growth inhibiting effect, preparation therefor and use of straw mushroom polysaccharide-selenium nanoparticle compound
CN112121060A
Application of chondroitin sulfate nano-selenium with antioxidant activity in preparation of antitumor drugs
CN115154615A
Application of chondroitin sulfate nano-selenium in preparation of angiogenesis inhibitor
CN117582451A
